Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium

Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of SORT1, the target for Theratechnologies’ oncology platform, in several cancer types.

NewsGuest UserOctober 27, 2022BIOOQuébecbiotechnology, theratechnologies, Oncology, EORTC

Imagia Cybernetics & Canexia Health Merge to Supercharge Precision Oncology Accessibility

Merger includes C$20 million investment to accelerate access to genomics-based testing for cancer treatment by combining Canexia Health’s advanced molecular cancer solutions with Imagia Cybernetics’ healthcare and AI expertise

NewsGuest UserFebruary 11, 2022Imagia, Canexia Health, Merge, Oncology